The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicinVincenzo Quagliariello, Nicola Maurea, Michelino De Laurentiis et al.|Cardiovascular Diabetology|2021Cited by 368
Ranolazine Protects from Doxorubicin-Induced Oxidative Stress and Cardiac DysfunctionCarlo G. Tocchetti, Nicola Maurea, Andrea Carpi et al.|European Journal of Heart Failure|2014Cited by 92
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to TrastuzumabVincenzo Quagliariello, Nicola Maurea, Margherita Passariello et al.|International Journal of Cardiology|2019Cited by 64
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitorsCarmine Fedele, Claudia De Lorenzo, Gennaro Riccio et al.|Breast Cancer Research and Treatment|2011Cited by 52
Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle trackingCarmela Coppola, Nicola Maurea, Claudia De Lorenzo et al.|OncoTargets and Therapy|2016Cited by 34